bos172722

BOS172722 is an orally bioavailable, selective small molecule inhibitor of the serine/threonine-protein kinase monopolar spindle 1 (Mps1; also known as TTK), a core component of the spindle assembly checkpoint (SAC) that ensures proper chromosome segregation during mitosis. By inhibiting Mps1/TTK, BOS172722 disrupts the SAC function in cancer cells, forcing them through cell division too rapidly and leading to fatal chromosomal segregation errors and cell death. This mechanism is particularly effective in highly proliferative cancers such as triple-negative breast cancer (TNBC), where it has shown synergistic antitumor activity when combined with paclitaxel chemotherapy. The drug was originally discovered at The Institute of Cancer Research (ICR), London, and is being developed by Boston Pharmaceuticals for oncology indications including TNBC and other advanced solid tumors[1][2][6][7][8].

Other names

1578245-44-9